SCHEMBL5300838

SCHEMBL5300838

Cc1ccc(-c2ccc(-c3cn4ncsc4n3)cc2)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 12/20 0.62
MAPT P10636 10/20 0.62
GAA P10253 2/20 0.53
SMN1; SMN2 Q16637 8/20 0.48
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
ALOX15 P16050 2/20 0.38
F2RL3 Q96RI0 4/20 0.38
PKM P14618 1/20 0.36
RECQL P46063 1/20 0.36
ALDH1A1 P00352 2/20 0.33
MITF O75030 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2996722 0.83 TP53 (0.71) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL5309504 0.77 SMN1; SMN2 (0.72) TP53MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL11146043 0.77 TP53 (0.71) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL5301366 0.74 SMN1; SMN2 (0.62) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL5305978 0.72 SMN1; SMN2 (0.40) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL18281450 0.71 SMN1; SMN2 (0.40) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL2540879 0.68 SMN1; SMN2 (0.41) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL2540334 0.68 APP (0.42) TP53MAPTGAASMN1; SMN2NPC1
SCHEMBL5305948 0.67 PIK3CG (0.44) TP53MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5310450 0.67 MAPT (0.43) TP53MAPTGAASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007034282-A2 DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2007-03-29 WO claimed
US-10933049-B2 Mobilizing agents and uses therefor THE UNIVERSITY OF QUEENSLAND (AU) 2021-03-02 US disclosed
US-20180185328-A1 MOBILIZING AGENTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2018-07-05 US disclosed
EP-3302710-A1 MOBILIZING AGENTS AND USES THEREFOR The University of Queensland (AU) 2018-04-11 EP disclosed
WO-2016191811-A1 MOBILIZING AGENTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180185328-A1 MOBILIZING AGENTS AND USES THEREFOR C3AR1, CSF3R, C5AR1 TP53 2107/4885MAPT 4884/4885GAA 4704/4885
US-10933049-B2 Mobilizing agents and uses therefor C3AR1, CSF3R, C5AR1 TP53 2107/4885MAPT 4884/4885GAA 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.